CEACAM5 and cancer: After the intervention, plasma levels of TMAO and cancer-associated biomarkers, such as Carcinoembryonic Antigen (CEA) 81, 82, should be determined via blood tests, coupled with an assessment of the changes of the composition of the intestinal microbiota of the intervention participants.